CompanyGraph
Ascletis Pharma Inc.
1672 · HKEX · China
Price data from its 2VJ listing on XSTU, quoted in EUR
ascletis.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $141,361, lower than 95% of all stocks globally
- PositionOperating margin is -73801.5%, lower than 95% of its Biotechnology peers (median -24.1%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
14.50BHKD1.85B · vs all stocks (USD)
Revenue (TTM)
1.11MHKD141.36K · vs all stocks (USD)
Beta
0.3920xvs all stocks
52-Week Change
-22.07%vs all stocks
Market Capitalization
14.50BHKD1.85B · vs all stocks (USD)
Enterprise Value
8.27BHKD1.05B · vs all stocks (USD)
Forward P/E
-32.04xvs Biotechnology peers
Price to Book (MRQ)
3.51xvs Biotechnology peers
Enterprise to Revenue
7.45Kxvs Biotechnology peers
Enterprise to EBITDA
-10.28xvs Biotechnology peers
Gross Margin
95.63%vs Biotechnology peers
Return on Assets (TTM)
-19.64%vs Biotechnology peers
Return on Equity (TTM)
-28.59%vs Biotechnology peers
Revenue (TTM)
1.11MHKD141.36K · vs all stocks (USD)
Revenue per Share (TTM)
0.0010HKDUpdated Sep 20, 2026Quarterly Revenue Growth
25.46%vs Biotechnology peers
Gross Profit (TTM)
475.44KHKD60.60K · vs all stocks (USD)
EBITDA (TTM)
-804.52MHKD-102.55M · vs all stocks (USD)
Net Income (TTM)
-692.79MHKD-88.31M · vs all stocks (USD)
Operating Cash Flow (TTM)
-668.82MHKD-85.25M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-425.92MHKD-54.29M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Sep 20, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
2.03MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.50MCNYFY2025 · Dec 31, 2025Gross Profit
527.00KCNYFY2025 · Dec 31, 2025Operating Income
-446.50MCNY-66.63M · vs all stocks (USD)
Pre-tax Income
-359.37MCNYFY2025 · Dec 31, 2025Income Tax Expense
506.00KCNYFY2025 · Dec 31, 2025Net Income
-359.88MCNYFY2025 · Dec 31, 2025EBIT
-359.21MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-369.01MCNYFY2025 · Dec 31, 2025Research & Development
409.05MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
30.27MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
65.68MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
164.00KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.3701CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.3701CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
972.51MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
972.51MSharesFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-414.47MCNYFY2025 · Dec 31, 2025Free Cash Flow
-416.07MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.44BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-359.37MCNYFY2025 · Dec 31, 2025Stock-based Compensation
7.63MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-65.51MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-71.00KCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
2.86MCNYFY2025 · Dec 31, 2025Capital Expenditures
-1.60MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-329.00KCNYFY2025 · Dec 31, 2025Purchase of Investments
-570.87MCNYFY2025 · Dec 31, 2025Sale of Investments
1.15BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
581.34MCNYFY2025 · Dec 31, 2025Common Stock Repurchase
-81.58MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
351.85MCNYFY2025 · Dec 31, 2025Shares Outstanding
986.09MSharesUpdated Sep 20, 2026Float Shares
211.20MSharesUpdated Sep 20, 2026% Held by Insiders
65.76%vs all stocks
% Held by Institutions
11.86%vs all stocks
Total Cash (MRQ)
2.66BHKD339.07M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.19HKDUpdated Sep 20, 2026Total Debt (MRQ)
4.38MHKD557.68K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0016xvs Biotechnology peers
Current Ratio (MRQ)
12.92xvs Biotechnology peers
Book Value per Share (MRQ)
2.55HKDUpdated Sep 20, 2026Total Assets
2.07BCNY308.37M · vs all stocks (USD)
Total Current Assets
1.92BCNYFY2025 · Dec 31, 2025Total Liabilities
132.26MCNYFY2025 · Dec 31, 2025Total Non-current Assets
145.81MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
4.67MCNYFY2025 · Dec 31, 2025Total Current Liabilities
127.59MCNYFY2025 · Dec 31, 2025Cash
1.44BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.44BCNYFY2025 · Dec 31, 2025Other Short-term Investments
457.36MCNYFY2025 · Dec 31, 2025Accounts Receivable
223.00KCNYFY2025 · Dec 31, 2025Inventory
1.87MCNYFY2025 · Dec 31, 2025Accounts Payable
1.34MCNYFY2025 · Dec 31, 2025Short-term Debt
2.87MCNYFY2025 · Dec 31, 2025Long-term Debt
2.29MCNYFY2025 · Dec 31, 2025Common Stock (Book)
679.00KCNYFY2025 · Dec 31, 2025Retained Earnings
-1.84BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.93BCNY288.63M · vs all stocks (USD)
Treasury Stock
83.43MCNYFY2025 · Dec 31, 202552-Week Low
7.95HKDUpdated Sep 20, 202652-Week High
19.86HKDUpdated Sep 20, 202652-Week Change
-22.07%vs all stocks
Beta
0.3920xvs all stocks
50-Day MA
9.71HKDUpdated Sep 20, 2026200-Day MA
13.15HKDUpdated Sep 20, 2026Avg 10-Day Volume
3.67MSharesUpdated Sep 20, 2026Avg 30-Day Volume
2.38MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
-0.6900HKDUpdated Sep 20, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -73801.5%, lower than 95% of its Biotechnology peers (median -24.1%)Significant
Operating margin: -738.015Industry median: -0.24Industry P5: -33.54Peers compared: 193
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.12×)Notable
Debt-to-equity: 0.00Industry median: 0.12Industry P5: 0.00Peers compared: 193
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.79
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $141,361, lower than 95% of all stocks globallySignificant
Revenue (USD): 141,360.916Global P5: 33,357,653.812
Market cap is $1.85B, above the global median of $1.18BNotable
Market cap (USD): 1,848,128,832.105Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Porton Pharma Solutions Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Mirxes Holding Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MeHow Innovative Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Novocure Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cofoe Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Fagron NV
Tier 1ProductionApproval-Gated PipelineFlowRule
Chengdu Olymvax Biopharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Mabwell (Shanghai) Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wedge Industrial Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
2 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Hangzhou Flariant Co., Ltd.
2 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shanghai New Centurion Net-A
2 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated